midazolam has been researched along with Carcinoma, Non-Small Cell Lung in 7 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase 1 drug-drug interaction study was conducted to evaluate the effect of multiple-dose administration of brigatinib on the single-dose pharmacokinetics of midazolam, a sensitive cytochrome P450 3A substrate." | 3.30 | A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. ( D'Arcangelo, M; Felip, E; Garrido, P; Gupta, N; Hanley, MJ; Vranceanu, F; Ye, M; Zhu, J, 2023) |
| "Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients with ALK + metastatic non-small cell lung cancer (NSCLC)." | 3.01 | Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors. ( de Braud, F; De Castro Carpeño, J; de Miguel Luken, MJ; Hurtado, FK; Lau, YY; Mau-Sorensen, M; McCulloch, T; Scott, J; Wang, D, 2021) |
| " We present results from 3 fixed-sequence studies evaluating drug-drug interactions for alectinib through CYP3A." | 2.84 | Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. ( Bogman, K; Bordogna, W; Cleary, Y; Dall, G; De Petris, L; Guerini, E; Martin-Facklam, M; Morcos, PN; Phipps, A; Viteri, S; Yu, L, 2017) |
| "Dyspnea and delirium are the two most commonly treated symptoms." | 2.53 | A Review of Palliative Sedation. ( Bobb, B, 2016) |
| "Etiology of stenosis included lung cancer (46 patients) esophageal cancer (14 patients) and other malignancies (8 patients)." | 1.38 | The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis. ( Anderson, P; McGrath, EE; Warriner, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Hanley, MJ | 1 |
| D'Arcangelo, M | 1 |
| Felip, E | 1 |
| Garrido, P | 1 |
| Zhu, J | 1 |
| Ye, M | 1 |
| Vranceanu, F | 1 |
| Gupta, N | 1 |
| Yalkinoglu, Ö | 1 |
| Becker, A | 1 |
| Krebs-Brown, A | 1 |
| Vetter, C | 1 |
| Lüpfert, C | 1 |
| Perrin, D | 1 |
| Heuer, J | 1 |
| Biedert, H | 1 |
| Hirt, S | 1 |
| Bytyqi, A | 1 |
| Bachmann, A | 1 |
| Strotmann, R | 1 |
| Hurtado, FK | 1 |
| de Braud, F | 1 |
| De Castro Carpeño, J | 1 |
| de Miguel Luken, MJ | 1 |
| Wang, D | 1 |
| Scott, J | 1 |
| Lau, YY | 1 |
| McCulloch, T | 1 |
| Mau-Sorensen, M | 1 |
| Parra-Guillen, ZP | 1 |
| Berger, PB | 1 |
| Haschke, M | 1 |
| Donzelli, M | 1 |
| Winogradova, D | 1 |
| Pfister, B | 1 |
| Früh, M | 1 |
| Gillessen, S | 1 |
| Krähenbühl, S | 1 |
| Kloft, C | 1 |
| Joerger, M | 1 |
| Bobb, B | 1 |
| Morcos, PN | 1 |
| Cleary, Y | 1 |
| Guerini, E | 1 |
| Dall, G | 1 |
| Bogman, K | 1 |
| De Petris, L | 1 |
| Viteri, S | 1 |
| Bordogna, W | 1 |
| Yu, L | 1 |
| Martin-Facklam, M | 1 |
| Phipps, A | 1 |
| McGrath, EE | 1 |
| Warriner, D | 1 |
| Anderson, P | 1 |
1 review available for midazolam and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A Review of Palliative Sedation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Delirium; Fatal Outcome; Female; Hum | 2016 |
4 trials available for midazolam and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Drug Interaction | 2023 |
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Cytochr | 2021 |
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytoc | 2017 |
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Topics: Adult; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3 | 2017 |
2 other studies available for midazolam and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2023 |
The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Bronchial Diseases; Bronchoscopy; Carcinoma; Carcinoma, Non-Small-Ce | 2012 |